Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tina Rydén-Bergsten"'
Autor:
Jane Knöchel, Catarina Nilsson, Björn Carlsson, Linda Wernevik, Alexis Hofherr, Peter Gennemark, Rasmus Jansson‐Löfmark, Rikard Isaksson, Tina Rydén‐Bergsten, Bengt Hamrén, Dinko Rekić
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 12, Pp 1569-1577 (2022)
Abstract Here, we show model‐informed drug development (MIDD) of a novel antisense oligonucleotide, targeting PCSK9 for treatment of hypocholesteremia. The case study exemplifies use of MIDD to analyze emerging data from an ongoing first‐in‐hum
Externí odkaz:
https://doaj.org/article/e7f981bc8d2c4134ac07a117e385317e
Autor:
Stanko Skrtic, Björn Tyrberg, Malin Broberg, Hans Ericsson, Volker Schnecke, Magnus Kjaer, Marcus Hompesch, Eva-Marie Andersson, Erik Ryberg, Alexander Aivazidis, Charlotte Wennberg Huldt, Lars Löfgren, Linda Morrow, Joanna Parkinson, Tina Rydén-Bergsten, Elaine Watkins, Maria Sörhede Winzell
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0208998 (2018)
AIMS/HYPOTHESIS:GPR44 (DP2, PTGDR2, CRTh2) is the receptor for the pro-inflammatory mediator prostaglandin D2 (PGD2) and it is enriched in human islets. In rodent islets, PGD2 is produced in response to glucose, suggesting that the PGD2-GPR44/DP2 axi
Externí odkaz:
https://doaj.org/article/14eb9641fd434a2fbeda8df2991ce6e8
Autor:
Dinko Rekić, Ivan Azarov, Jane Knöchel, Victor Sokolov, Catarina Nilsson, Linda Wernevik, David Han, Tina Rydén‐Bergsten, Ahmad Ebrahimi, Corina Dota, Björn Carlsson
Publikováno v:
British Journal of Clinical Pharmacology. 88:4839-4844
AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolaemia. A prespecified concentration-QT analysis was performed based on data from a single ascending dose s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134aac677ccd322d75dbf14e4da7d520
https://doi.org/10.1111/bcp.15425
https://doi.org/10.1111/bcp.15425
Autor:
Catarina Nilsson, Rosanne M. Crooke, Nigel Davies, Birgitta Rosengren, Brett P. Monia, Eva Hurt-Camejo, Cristina S. J. Rocha, Tina Rydén-Bergsten, Stan Riney, Daniel Lindén, Rosie Z. Yu, Yanfeng Wang, Peter Gennemark, Anna Tivesten, Dorota Kakol-Palm, Ulf Andersson, Lloyd G. Tillman, Marie Elebring, Björn Carlsson, Mikko Hölttä, Jane Knöchel, Linda Wernevik, Rasmus Jansson-Löfmark, Niclas Clemmensen, Rikard Isaksson, Katrin Walter, Richard S. Geary, Dinko Rekić
Publikováno v:
Science Translational Medicine. 13
Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 inhibitors are administered via subcutaneous injection. We present a highly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197948bccc867454748627a58e0b6234
https://doi.org/10.1126/scitranslmed.abe9117
https://doi.org/10.1126/scitranslmed.abe9117
Autor:
Erik Ryberg, Simen W. Schive, David M. Smith, Shadab Abadpour, Stanko Skrtic, Tina Rydén-Bergsten, Maria Sörhede Winzell, Björn Tyrberg, Olle Korsgren, Hanne Scholz, Charlotte Wennberg Huldt, Peter Gennemark
Aims/hypothesis Inflammatory signals and increased prostaglandin synthesis play a role during the development of diabetes. The prostaglandin D2 (PGD2) receptor, GPR44/DP2, is highly expressed in human islets and activation of the pathway results in i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcc103a4567c7ac7049e2dca816998c4
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-166204
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-166204
Autor:
Shadab, Abadpour, Björn, Tyrberg, Simen W, Schive, Charlotte Wennberg, Huldt, Peter, Gennemark, Erik, Ryberg, Tina, Rydén-Bergsten, David M, Smith, Olle, Korsgren, Stanko, Skrtic, Hanne, Scholz, Maria Sörhede, Winzell
Publikováno v:
Diabetologia
Aims/hypothesis Inflammatory signals and increased prostaglandin synthesis play a role during the development of diabetes. The prostaglandin D2 (PGD2) receptor, GPR44/DP2, is highly expressed in human islets and activation of the pathway results in i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6f4150d20a227e4ea67fea3e37a49c5
https://pubmed.ncbi.nlm.nih.gov/32350565
https://pubmed.ncbi.nlm.nih.gov/32350565
Autor:
Elaine Watkins, Charlotte Wennberg Huldt, Joanna Parkinson, Erik Ryberg, Volker Schnecke, Eva-Marie Andersson, Hans Ericsson, Björn Tyrberg, Marcus Hompesch, Stanko Skrtic, Tina Rydén-Bergsten, Linda Morrow, Lars Löfgren, M Kjaer, Alexander Aivazidis, Malin A. Broberg, Maria Sörhede Winzell
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 12, p e0208998 (2018)
PLoS ONE, Vol 13, Iss 12, p e0208998 (2018)
Aims/hypothesis GPR44 (DP2, PTGDR2, CRTh2) is the receptor for the pro-inflammatory mediator prostaglandin D2 (PGD2) and it is enriched in human islets. In rodent islets, PGD2 is produced in response to glucose, suggesting that the PGD2-GPR44/DP2 axi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd4e2b2cc1865878af2a6e230a3732ac
http://europepmc.org/articles/PMC6296667
http://europepmc.org/articles/PMC6296667
Autor:
Susanne Johansson, Maria Leonsson-Zachrisson, David P. Rosenbaum, Peter J. Greasley, Tina Rydén-Bergsten, Geoffrey A. Block, Bergur V. Stefánsson, Mikael Knutsson, Björn Carlsson
Publikováno v:
Clinical Journal of the American Society of Nephrology. 11:1597-1605
Interdialytic weight gain in patients on hemodialysis is associated with adverse cardiovascular outcomes and increased mortality. The degree of interdialytic weight gain is influenced by sodium intake. We evaluated the effects of tenapanor (AZD1722 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a8a44f41c273e6a6d884fa616b82e9
https://doi.org/10.2215/cjn.09050815
https://doi.org/10.2215/cjn.09050815
Publikováno v:
Diabetes and Vascular Disease Research. 10:263-269
The second Diabetes Glucose and Myocardial Infarction (DIGAMI 2) study randomised patients with diabetes and myocardial infarction to insulin or oral-based treatment. To determine the effects of insulin-based treatment, the Diabetes Treatment Satisfa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56ab24e9dc2e5b0487242c17ab6523b
https://doi.org/10.1177/1479164112463711
https://doi.org/10.1177/1479164112463711
Publikováno v:
PharmacoEconomics. 15:535-550
Heart failure (HF) is a common and expensive cardiovascular disease, in economic terms as well as in lives lost. Angiotensin converting enzyme (ACE) inhibitors have been shown to significantly reduce mortality and hospitalisation in HF. However, rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a0cb757c064b23e20844842c45b0a3f
https://doi.org/10.2165/00019053-199915060-00002
https://doi.org/10.2165/00019053-199915060-00002